Crecheck
AssetAlso Crecheck Tablet 2.5 mg
HMG-CoA reductase inhibitor that lowers low-density lipoprotein cholesterol
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- 3
- Indications
- 492
- Trials
- 1
- Developer
Indications
3Hypertension
Phase 3, Unknown, NCT04659070, clinicaltrials.gov, 7 Oct 2026
Primary hypercholesterolemia
Phase 3, Unknown, NCT04659070, clinicaltrials.gov, 7 Oct 2026
Combined hyperlipidemia
Phase 1, Completed, NCT06475872, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials492
- Evidence for its targets3
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.